FDA approves first treatment for thyroid eye disease |
Clinical News
eMediNexus Coverage from: 
FDA approves first treatment for thyroid eye disease

0 Read Comments                

The U.S. Food and Drug Administration (FDA) has approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease, a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to be pushed forward and bulge outwards (proptosis). The approval represents the first drug approved for the treatment of thyroid eye disease… (FDA, January 21, 2020)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now